Journal article
Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance
Abstract
Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment and outcomes of chronic myeloid leukemia (CML). Despite their significant impact on the management of CML, there is growing evidence that TKIs may cause cardiovascular and/or metabolic complications. In this review, we present the current evidence regarding the cardiovascular safety profiles of BCR-ABL TKIs. Methodological challenges of studies that reported the cardiovascular …
Authors
Aghel N; Delgado DH; Lipton JH
Journal
Vascular Health and Risk Management, Vol. 13, No. 0, pp. 293–303
Publisher
Taylor & Francis
Publication Date
August 4, 2017
DOI
10.2147/vhrm.s108874
ISSN
1176-6344